JP2023539341A5 - - Google Patents
Info
- Publication number
- JP2023539341A5 JP2023539341A5 JP2023514067A JP2023514067A JP2023539341A5 JP 2023539341 A5 JP2023539341 A5 JP 2023539341A5 JP 2023514067 A JP2023514067 A JP 2023514067A JP 2023514067 A JP2023514067 A JP 2023514067A JP 2023539341 A5 JP2023539341 A5 JP 2023539341A5
- Authority
- JP
- Japan
- Prior art keywords
- double
- stranded sirna
- section
- stranded
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073304P | 2020-09-01 | 2020-09-01 | |
| US63/073,304 | 2020-09-01 | ||
| PCT/US2021/048611 WO2022051332A1 (en) | 2020-09-01 | 2021-09-01 | Dux4 inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026020017A Division JP2026077722A (ja) | 2020-09-01 | 2026-02-10 | Ｄｕｘ４阻害剤およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539341A JP2023539341A (ja) | 2023-09-13 |
| JP2023539341A5 true JP2023539341A5 (OSRAM) | 2024-08-23 |
Family
ID=80492176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514067A Pending JP2023539341A (ja) | 2020-09-01 | 2021-09-01 | Ｄｕｘ４阻害剤およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230348906A1 (OSRAM) |
| EP (1) | EP4208548A4 (OSRAM) |
| JP (1) | JP2023539341A (OSRAM) |
| AR (1) | AR123420A1 (OSRAM) |
| AU (1) | AU2021337595A1 (OSRAM) |
| CA (1) | CA3189861A1 (OSRAM) |
| TW (1) | TW202227626A (OSRAM) |
| WO (1) | WO2022051332A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| BR112022019889A2 (pt) | 2020-04-02 | 2023-03-07 | Mirecule Inc | Inibição direcionada com o uso de oligonucleotídeos modificados geneticamente |
| AU2021342155A1 (en) | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| MX2024003266A (es) | 2021-09-16 | 2024-04-03 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral. |
| WO2023185946A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州瑞博生物技术股份有限公司 | 一种寡核苷酸缀合物、含有该寡核苷酸缀合物的组合物及制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| EP2606152B2 (en) * | 2010-08-18 | 2025-03-12 | Fred Hutchinson Cancer Center | Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd) |
| AU2012286994B2 (en) * | 2011-07-25 | 2017-08-10 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of DUX4 |
| WO2016115490A1 (en) * | 2015-01-16 | 2016-07-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of dux4 |
| EP3668997A4 (en) * | 2017-10-02 | 2021-05-19 | Research Institute at Nationwide Children's Hospital | SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE |
| CN120247995A (zh) * | 2018-05-30 | 2025-07-04 | 诺华股份有限公司 | 脂质修饰的核酸化合物和方法 |
| WO2020028134A1 (en) * | 2018-07-30 | 2020-02-06 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating cancer |
| US20220193250A1 (en) * | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
-
2021
- 2021-09-01 CA CA3189861A patent/CA3189861A1/en active Pending
- 2021-09-01 EP EP21865016.6A patent/EP4208548A4/en active Pending
- 2021-09-01 AU AU2021337595A patent/AU2021337595A1/en active Pending
- 2021-09-01 TW TW110132422A patent/TW202227626A/zh unknown
- 2021-09-01 AR ARP210102453A patent/AR123420A1/es unknown
- 2021-09-01 WO PCT/US2021/048611 patent/WO2022051332A1/en not_active Ceased
- 2021-09-01 US US18/043,520 patent/US20230348906A1/en active Pending
- 2021-09-01 JP JP2023514067A patent/JP2023539341A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI880645B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP7829035B2 (ja) | アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法 | |
| US20160201063A1 (en) | Epigenetic regulators of frataxin | |
| JP2025504863A (ja) | タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法 | |
| EP3272868A1 (en) | Organic compositions to treat kras-related diseases | |
| AU2017290231A1 (en) | Exon skipping oligomers for muscular dystrophy | |
| JP2023538284A (ja) | Ｐｌｐ１発現を阻害するための組成物及び方法 | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| TW202321452A (zh) | 用於抑制血管生成素樣３（ａｎｇｐｔｌ３）蛋白表達的組合物和方法 | |
| CN118202049A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| KR20240111795A (ko) | B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법 | |
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| CN118202053A (zh) | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 | |
| JP2025504474A5 (OSRAM) | ||
| CN115137742A (zh) | 一种用于治疗肥胖症的rna递送系统 | |
| JP2004528851A6 (ja) | 上皮成長因子受容体のアンチセンスオリゴヌクレオチド | |
| JP2004528851A (ja) | 上皮成長因子受容体のアンチセンスオリゴヌクレオチド | |
| WO2026050125A1 (en) | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder | |
| WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
| WO2025090254A1 (en) | Adnp syndrome antisense treatment | |
| TW202345873A (zh) | 調節ｓｃａｐ活性之組合物及方法 | |
| WO2022206821A1 (zh) | 一种用于治疗帕金森的rna递送系统 | |
| JP2026077722A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| WO2024169907A1 (zh) | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 | |
| KR20260040626A (ko) | 안지오텐시노겐을 표적으로 하는 올리고뉴클레오티드 및 이의 용도 |